Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Elisabeth Douglas Galsgaard"'
Autor:
Mira Thing, Mikkel Parsberg Werge, Nina Kimer, Liv Eline Hetland, Elias Badal Rashu, Puria Nabilou, Anders Ellekaer Junker, Elisabeth Douglas Galsgaard, Flemming Bendtsen, Johnny Laupsa-Borge, Adrian McCann, Lise Lotte Gluud
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Alterations in the production of short-chain fatty acids (SCFAs) may reflect disturbances in the gut microbiota and have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD). We assessed plasma SCFAs in
Externí odkaz:
https://doaj.org/article/011417fdb1124f8383c726d628e38b21
Autor:
Kasper Vadstrup, Elisabeth Douglas Galsgaard, Jens Gerwien, Marianne Kajbæk Vester-Andersen, Julie Steen Pedersen, Julie Rasmussen, Søren Neermark, Marianne Kiszka-Kanowitz, Teis Jensen, Flemming Bendtsen
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155335 (2016)
Crohn's disease (CD) is a chronic illness demanding better therapeutics. The marketed biologics only benefit some patients or elicit diminishing effect over time. To complement the known methods in drug development and to obtain patient specific drug
Externí odkaz:
https://doaj.org/article/b9b2ab5d62134c26be2a5956bd640a67
Autor:
Jenny Norlin, Lisbeth Nielsen Fink, Peter Helding Kvist, Elisabeth Douglas Galsgaard, Ken Coppieters
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0152315 (2016)
Diabetic nephropathy (DN) is one of the most severe complications of diabetes and remains the largest cause of end-stage renal disease in the Western world. Treatment options are limited and novel therapies that effectively slow disease progression a
Externí odkaz:
https://doaj.org/article/6970ee9b774f48e38bbbbf82133a98a4
Autor:
Elisabeth Douglas Galsgaard
Publikováno v:
Journal of Endocrinology; Apr2009, Vol. 201 Issue 1, p115-128, 14p